HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.24
+0.01 (+2.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.23
Open0.24
Bid0.00 x 900
Ask0.70 x 800
Day's Range0.23 - 0.24
52 Week Range0.15 - 0.65
Volume199,523
Avg. Volume238,304
Market Cap11.339M
Beta-0.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?
    Simply Wall St.4 months ago

    How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?

    After reading Hemispherx Biopharma Inc’s (AMEX:HEB) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...

  • Zacks Small Cap Research8 months ago

    HEB: Recent Advancements…What Do They Imply?

    With the stock up 50% over the past 3 months, we believe HEB (HEB) is starting to look like an attractive investment.  Since our prior report (November 14, 2017), Hemispherx has made some progress in their Ampligen product development cycle that could potentially prove positive for their stock. ➢ Hemispherx obtained ANMAT approval in Argentina, one of South America's largest markets, in August 2017.  Ampligen is available in Europe through an Early Access Program (EAP).  In the U.S., Ampligen has undergone two randomized, placebo-controlled pivotal trials.  The firm is currently focused on preparing an NDA and confirmatory trial for Ampligen.  Meanwhile, Ampligen is available for patients under a cost recovery program (compassionate care) – which means that Hemispherx cannot make a profit on Ampligen sales but can recover its costs.  Hemispherx received an approval from the FDA to increase the price of one vial from $75 to $200.

  • GuruFocus.com8 months ago

    Here's Why the 2 Latest Hemispherx BioPharma Announcements Are Important

    A look at the latest news from Hemispherx and what it means for the company

  • Capital Cube9 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
    Capital Cube10 months ago

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017

    Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Pfizer Inc., Baxter International Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, GlaxoSmithKline plc Sponsored ADR and ... Read more (Read more...)

  • HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?
    Zacks Small Cap Research10 months ago

    HEB: Will The Current Improvements Cause A Turnaround For Hemispherx?

    Currently, commercialization efforts for both drugs have been hampered for different reasons.  The company faced some manufacturing hurdles related to Alferon.  However, the company has already taken steps towards increasing efficiency for production of Alferon.  The FDA rejected the NDA for Ampligen.  However, the company is working towards addressing the concerns raised by the FDA.  The company is also open to collaborative opportunities including out-licensing, co-research, co-development, co-promotion as well as co-marketing their product candidates.  Overall, we do see some significant headwinds for Hemispherix in the near term, however we believe there is a large market potential for the drugs and see significant value if they are able to overcome current roadblocks.

  • Is Hemispherx Biopharma Inc (HEB) Thriving Or Barely Surviving In The Healthcare Sector?
    Simply Wall St.11 months ago

    Is Hemispherx Biopharma Inc (HEB) Thriving Or Barely Surviving In The Healthcare Sector?

    Hemispherx Biopharma Inc (AMEX:HEB), a USD$10.43M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...

  • What’s The Outlook For Loss-Making Hemispherx Biopharma Inc (HEB)?
    Simply Wall St.last year

    What’s The Outlook For Loss-Making Hemispherx Biopharma Inc (HEB)?

    As the USD $9.07M market cap Hemispherx Biopharma Inc (AMEX:HEB) released another year of negative earnings, investors may be on edge waiting for breakeven. The single most important question toRead More...